Medicines for Europe
07.05.2026 - The Biosimilar Advantage: Powering patient access and industrial resilience
16.04.2026 - Impact of the ongoing conflict in the Middle East on the supply of medicinal products to Europe
06.03.2026 - Reactive statement
20.01.2026 - Parliament makes the Critical Medicines Act meaningful but significant risks to future access persist
07.01.2026 - Steffen Saltofte (Zentiva) named President of Medicines for Europe
15.12.2025 - Environment omnibus and impact study fail to address huge flaws in Urban waste water treatment directive
15.10.2025 - European Commission risks repeating past mistakes in Urban Wastewater Treatment Directive cost study
24.09.2025 - Industry unites for a bold Critical Medicines Act that prioritises secure supply of medicines for patients
01.09.2025 - SANT Committee prioritises manufacturing competitiveness in draft report on the Critical Medicines Act
10.07.2025 - Medicines for Europe intervenes in legal challenge against Urban Wastewater Treatment Directive's EPR scheme
14.07.2021 - Slovenian Presidency Council of the EU - Priorities
22.04.2021 - European patients need improved access to biosimilar medicines
30.03.2021 - New report assesses progress on biosimilar medicine policies across Europe
17.03.2021 - Medicines for Europe statement to EUCO representatives in view of the meeting on Covid-19 and industrial policy
19.02.2021 - No further excuse to delay digital regulatory infrastructure for medicines after Covid-19 pandemic
19.02.2021 - A new medicines trade and health security agenda for the European Commission
25.11.2020 - Press release
17.09.2020 - Press release







